Last updated on January 2020

Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata

Brief description of study

This was an open-label, randomized and single-arm phase study. Patients with severe Alopecia Areata were randomized via interactive voice/web response system 1:1 to receive either 150mg qd or 200 mg qd of oral Jaktinib Dihydrochloride Monohydrate

Detailed Study Description

Clinical trial of Tofacitinib, Ruxolitinib, and Baricitinib have shown promising prospects for the treatment of alopecia areata (especially severe alopecia areata) with JAK inhibitorsJaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 JAK2 and JAK3This was a phase , open-label, Multi-center,randomized study to Evaluating Safety and Efficacy of oral Jaktinib Dihydrochloride Monohydrate (150mg qd or 200 mg qd) for the treatment of severe Alopecia Areata.

Clinical Study Identifier: NCT04034134

Find a site near you

Start Over